source
- Regeneron expands partnership with CytomX as other pharma partners exitRegeneron announced it will deepen its collaboration with CytomX Therapeutics, a Bay Area biotech. The decision follows CytomX losing several partnership agreements with other large pharmaceutical…
- Eli Lilly signs up to $1.9B deal with Ascidian Therapeutics for RNA editing in kidney diseaseAscidian Therapeutics recently presented early data indicating that its novel RNA‑editing approach to repair faulty genes appears safe in humans, focusing on kidney disease applications. Eli Lilly…